> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Zymeworks Turns Profitable On $250 Million Ziihera Milestone And Raises Its Revenue Outlook
- URL: https://www.bullished.co/zymeworks-turns-profitable-on-250-million-ziihera-milestone-and-raises-its-revenue-outlook-5787811b/
- Published: 2026-11-09T22:36:57.000Z
- Updated: 2026-11-09T22:36:56.000Z
- Description: The higher forecast depends on Roche antitrust clearance, while Theravance acquisition costs pushed selling and administrative expenses higher.
- Author: Matteo Parrino
- Tags: Deals, ZYME, Industry: Healthcare

[Zymeworks](https://www.bullished.co/tag/zyme/), which develops antibody-based medicines and earns revenue from licensed healthcare assets, posted a $173.7 million third-quarter profit after earning a [$250 million milestone](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000067/zyme-20261109.htm?ref=bullished.co) tied to Ziihera's U.S. approval. Monday's earnings release also raised its annual revenue outlook, though that forecast depends on antitrust clearance for its Roche collaboration.

## Ziihera Changes The Quarter's Math

Revenue reached [$256.5 million](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000067/ex991q32026%5Fearningsxrelea.htm?ref=bullished.co), compared with $27.6 million a year earlier. The approval milestone from Jazz Pharmaceuticals was the main driver, turning a year-earlier $19.6 million loss into profit; Zymeworks received the payment in October.

The milestone followed August approval of Ziihera-containing treatments for first-line HER2-positive advanced gastroesophageal adenocarcinoma. A $25 million Johnson & Johnson development milestone had contributed to the year-earlier quarter's revenue.

Ziihera royalties were [$2.3 million](https://www.globenewswire.com/news-release/2026/11/09/3398944/0/en/zymeworks-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html?ref=bullished.co), mostly from Jazz's U.S. sales. Jazz and BeOne Medicines commercialize the antibody through global partnerships, giving Zymeworks royalties and milestone opportunities alongside its own cancer and autoimmune research.

## Higher Guidance Depends On Roche

Zymeworks now expects 2026 revenue of [$337 million–$351 million](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000067/zyme-20261109.htm?ref=bullished.co), versus $278 million–$292 million previously. It also lifted its adjusted earnings forecast before interest, taxes, depreciation and amortization to $176 million–$190 million from $114 million–$128 million, excluding future transactions.

The company expects antitrust clearance for the Roche collaboration during the fourth quarter. Under the agreement signed October 22, Roche received [exclusive worldwide rights](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000055/zyme-20261022.htm?ref=bullished.co) to experimental cancer drug ZW209\. Zymeworks is eligible for $55 million upfront, and Roche will fund the initial early-stage trial and take responsibility for subsequent global development and commercialization.

Kenneth Galbraith, Zymeworks' chair and chief executive officer, described the financing approach: “Just as importantly, we can increasingly match the capital and ownership structure to each opportunity, whether acquiring and operating a business, partnering an asset, licensing a program or bringing in external venture capital, [without assuming that](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000067/ex991q32026%5Fearningsxrelea.htm?ref=bullished.co) every opportunity must be funded entirely from our balance sheet.”

## Theravance Adds Revenue And Costs

Zymeworks [completed its purchase](https://www.sec.gov/Archives/edgar/data/0001937653/000119312526399383/d270232dex991.htm?ref=bullished.co) of Theravance Biopharma on September 23, adding recurring commercial cash flow from YUPELRI. Theravance supplied approximately $1.5 million of revenue during seven days of ownership in the quarter.

Selling and administrative expenses reached [$42.7 million](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000067/ex991q32026%5Fearningsxrelea.htm?ref=bullished.co), versus $14.1 million a year earlier. Acquisition-related severance and professional fees were the main causes, together with higher stock-based pay. Research spending was $36.1 million, compared with $35.6 million.

Zymeworks expects to eliminate $13 million–$15 million in annualized overhead and corporate costs following the acquisition. Net other expense was $4.4 million, versus $3.8 million of income a year earlier, principally because of interest on its March Royalty Pharma financing and lower investment income.

The company bought back 534,381 shares for $14 million during the quarter. Across the first nine months, it repurchased 5,737,790 shares for $140.4 million. Zymeworks said [$600 million of financing](https://www.globenewswire.com/news-release/2026/11/09/3398944/0/en/zymeworks-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html?ref=bullished.co) through notes, including royalty-backed debt, supported the acquisition and repurchases while limiting equity dilution.

Zymeworks plans to discuss its research portfolio at an R&D Day in New York on February 11, 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Zymeworks Inc. (ZYME)](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000067/zyme-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex991q32026\_earningsxrelea.htm — Zymeworks Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000067/ex991q32026%5Fearningsxrelea.htm?ref=bullished.co) — SEC EDGAR
- [Zymeworks Provides Corporate Update and Reports Third](https://www.globenewswire.com/news-release/2026/11/09/3398944/0/en/zymeworks-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com
- [8-K filed 2026-10-23 — Zymeworks Inc. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001937653/000193765326000055/zyme-20261022.htm?ref=bullished.co) — SEC EDGAR
- [8-K filed 2026-09-23 — Zymeworks Inc. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001937653/000119312526399383/d270232dex991.htm?ref=bullished.co) — SEC EDGAR

### More on Zymeworks

- [Roche Will Pay Zymeworks $55 Million Upfront For Rights To Lung Cancer Drug ZW209](https://www.bullished.co/roche-will-pay-zymeworks-55-million-upfront-for-rights-to-lung-cancer-drug-zw209-cc3b53ce/)

[All Zymeworks (ZYME) coverage →](https://www.bullished.co/tag/zyme/)